retatrutide calculator Dosage Calculator: How Dosing Works Retatrutide Reconstitution & Dosing Calculator

Do not move your tongue around

In the REDEFINE 1 clinical trial, patients treated with the combination achieved a mean weight loss of 22.7% at 68 weeks, and more than 40% of participants achieved at least a 25% reduction in body weight

Temperature-controlled logistics are employed to maintain chemical stability and prevent degradation

Retatrutide is a new approach to treat obesity and early results suggest it could cause more weight loss than other treatments

Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)